



American College of
Emergency Physicians®

Washington, D.C. Office
2121 K Street, NW
Suite 325
Washington, D.C. 20037-1801

202-728-0610
800-320-0610
202-728-0617 -- Fax

www.acep.org

Board of Directors

Frederick C. Blum, MD, FACEP, FAAP
President
Brian F. Keaton, MD, FACEP
President-Elect
John D. Bibb, MD, FACEP
Chairman of the Board
Linda L. Lawrence, MD, FACEP
Vice President
Nicholas J. Jouriles, MD, FACEP
Secretary-Treasurer
Robert E. Suler, DO, MHA, FACEP
Immediate Past President
Kathleen M. Cowling, DO, MS, FACEP
Angela F. Gardner, MD, FACEP
Cherri D. Hobgood, MD, FACEP
Ramon W. Johnson, MD, FACEP
Arthur L. Kellermann, MD, FACEP
Sandra M. Schneider, MD, FACEP
David C. Seaberg, MD, CPE, FACEP
David P. Sklar, MD, FACEP

Council Officers

Todd B. Taylor, MD, FACEP
Speaker
Bruce A. MacLeod, MD, FACEP
Vice Speaker

Executive Director

Dean Wilkerson, JD, MBA, CAE

**FDA Presentation Abstract; Docket No 2006D-0331;
Conduct of Emergency Clinical Research; Public Hearing**

Submitted by Edward P. Sloan, MD, FACEP, and Charles B. Cairns, MD, FACEP, on behalf of the American College of Emergency Physicians.

The American College of Emergency Physicians (ACEP) appreciates the opportunity to revisit the Exception from Informed Consent for Emergency Research and the opportunity to comment on the draft guidance.

In response to FDA questions (1), (2) and (4), ACEP believes that the draft guidance has been responsive to researchers' concerns and helped clarify the requirements in CFR 50:24.

Emergency research advances the field of Emergency Medicine and improves clinical acute care. Emergency research should be supported in whatever means are possible, including the use of the consent exception and the guidelines that govern its use. The recently released Institute of Medicine report on the *Future of Emergency Care* describes the scarcity of clinical effectiveness trials for the treatment of critically ill or injured patients, especially in the pre-hospital setting. Thus, the continued conduct of research in this setting is especially critical.

Regarding the work of the FDA, NIH, and IRBs to date, ACEP believes the following:

1. The agencies that have been responsible for this research guidance and support have done an excellent job in crafting the regulations and working with investigators to implement them in support of quality emergency research.
2. ACEP looks forward to working with all concerned federal agencies, local IRBs and advocacy groups, all emergency health care societies and providers, as well as individual citizens going forward as we strive to improve patient outcomes through the conduct of ethical and effective emergency research that utilizes the exception to informed consent.

Any revisions to current regulations should serve to expand the ability to perform the highest quality emergency research and to enhance patient protections through fairness, openness, and use of all media that provide explicit detail regarding the research. Burdens should not be placed upon researchers in a way that is disproportionate to the inherent risks and need to advance emergency care through the conduct of quality emergency research utilizing the exception to informed consent.

In response to FDA question (7), the use of community consultation is relatively new in research that merits further study. While the overall process has been well received, many unresolved issues remain, such as which community to consult, who counts as a community representative or member to be consulted with, and what is the purpose of this consultation. An important step is to conduct research on community consultation in order to identify best practices before further guidance can be given. Furthermore, ACEP suggests that if the goals of

2006D-0331

CS

community consultation and public disclosure could be more clearly delineated, these goals would also guide investigators and sponsors in enhancing the process of conducting clinical trials while providing quality emergency care.

Per FDA question (8), ACEP suggests that current opt-out mechanisms may be necessary, but not sufficient to identify patients deferring participation in the research inclusion. Although patients in extremis cannot be assumed to be competent to provide informed consent, they should be assumed to be competent to reuse participation in research that utilized the exception. As such, ACEP suggests that patients should be briefly asked if they wish to participate in the research, and if they decline to participate, their wishes should be honored.

Per FDA question (9), ACEP believes that community consultation could not only provide information on the study, but could also help the IRB identify risks and protections from risk.

ACEP suggests that the use of the exception must be explicitly stated to all who might be at risk or benefit from the research, including the hospital, its staff and IRB, the population of potential patients who might become involved in the research, and the governmental agencies that might oversee the research. This includes full notification of the results of all IRB deliberations, including those who decline to participate, the results of the community consultations and public disclosure and the results of the clinical trial itself.

In response to FDA question (11), ACEP suggests that there should be a record of all suggestions generated by community consultation and how the IRB and investigator handled them. This documentation should be the responsibility of the sponsor and available on the FDA Web site or Clinicaltrials.gov.

Regarding FDA questions (13) and (14), ACEP believes that while full study protocols do not necessarily need to be formally presented to communities or the general public, these study details should be available upon request.

Per FDA questions (16) and (17), ACEP believes that the results of clinical investigation should be disclosed when the study has been peer reviewed and ready for publication. The results of all studies that utilize the exception of informed consent should be published in the medical literature, even if the results of the clinical trial do not demonstrate benefit with the tested therapy or procedure. Journal editors should be encouraged to support publication of negative trials that utilize the exception in order to assist with the process of utilizing the exception.

In summary, ACEP supports fully the processes necessary to conduct high quality emergency research, including this review of the exception to informed consent process. It is through continued dialogue on important matters such as this that clinical science will improve emergency care and optimize outcomes for patients who we serve on a daily basis in the out-of-hospital and Emergency Department settings.

Tinch, Latroy D

From: Barbara Marone [bmarone@acep.org]
Sent: Wednesday, September 20, 2006 4:20 PM
To: Crescenzi, Terrie
Subject: Registration and abstract
Attachments: FDA Abstract.doc

Terrie:

After I filled out the info on the website, I got an error message saying the network admin needed to be contacted. So - if you would be so kind as to make sure this gets to the right place, I'd really appreciate it. Two members of ACEP will attend and want to make a statement. Abstract attached. They will somehow divide issues or you can arbitrarily cut it in half or whatever works for your purposes.

Since they are trying to do a 1-day trip, if they could be on between 10 - 3, it would be great. Assume you'll have a lot of logistics, though. Thanks for your help.

<<FDA Abstract.doc>>

Charles B. Cairns, MD, FACEP
Associate Professor
Associate Chief, Emergency Medicine
Duke University Medical Center
Director of Emergency Medicine Research
Duke Clinical Research Institute
2400 Pratt Street
Durham, NC 27705
Tel (919) 668-8279
Fax (919) 668-7023
Email: Charles.Cairns@duke.edu

Edward P. Sloan, MD, MPH, FACEP
Professor
Department of Emergency Medicine
University of Illinois at Chicago
Mail Code 724
808 South Wood Street
Chicago, IL 60612
Phone 312 413-7490
Fax 312 355 1269
edsloan@uic.edu

Barbara Marone
Director Federal Affairs
American College of Emergency Physicians
2121 K St. N.W. Suite 325
Washington, DC 20037
(202) 728-0610
mailto:bmarone@acep.org
http://www.acep.org